IMMUNOREACTIVITY FOR P53 PROTEIN IN MALIGNANT MESOTHELIOMA AND NONNEOPLASTIC MESOTHELIUM

被引：57
|
作者：
RAMAEL, M
LEMMENS, G
EERDEKENS, C
BUYSSE, C
DEBLIER, I
JACOBS, W
VANMARCK, E
机构：
[1] Department of Pathology, University Hospital Antwerp, University of Antwerp (U.I. A.), Edegem, 2650
来源：
JOURNAL OF PATHOLOGY | 1992年 / 168卷 / 04期
关键词：
MESOTHELIOMA; P53; PROTEIN; SUPPRESSOR ONCOGENE; IMMUNOHISTOCHEMISTRY; MESOTHELIUM;
D O I：
10.1002/path.1711680406
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The presence of p53 protein in non-neoplastic pleural mesothelium (40 cases) and in human malignant mesothelioma (36 cases) was assessed immunohistochemically using the antibodies DO7, CM-1, and PAb240. In a quarter of the malignant mesotheliomas, there was nuclear immunoreactivity for p53 protein with both the DO7 and CM-I antibodies. There were no statistically significant differences between the various mesothelioma subtypes (P>0.05). No immunoreactivity was found with the PAb240 antibody, suggesting absence of mutant-type p53 protein. Non-neoplastic mesothelium was not immunoreactive with any of the antibodies. We conclude that there is immunoreactivity for p53 protein in some mesotheliomas. p53 protein immunoreactivity could be used to discriminate between neoplastic and reactive mesothelium.
引用
收藏
页码：371 / 375
页数：5
相关论文
共 50 条
  • [41] IS IMMUNOREACTIVITY FOR P53 USEFUL IN DISTINGUISHING BENIGN FROM MALIGNANT EFFUSIONS - LOCALIZATION OF P53 GENE-PRODUCT IN BENIGN MESOTHELIAL AND ADENOCARCINOMA CELLS
    WALTS, AE
    SAID, JW
    KOEFFLER, HP
    MODERN PATHOLOGY, 1994, 7 (04) : 462 - 468
  • [42] P53-PROTEIN EXPRESSION IN NONNEOPLASTIC LESIONS AND BENIGN AND MALIGNANT NEOPLASMS OF SOFT-TISSUE
    TOS, APD
    DOGLIONI, C
    LAURINO, L
    BARBARESCHI, M
    FLETCHER, CDM
    HISTOPATHOLOGY, 1993, 22 (01) : 45 - 50
  • [43] Computational protein chemistry of p53 and p53 peptides
    Brandt-Rauf, PW
    Rosal, RV
    Fine, RL
    Pincus, MR
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2004, 9 : 2778 - 2787
  • [44] Pharmacological targeting of p53 through RITA is an effective antitumoral strategy for malignant pleural mesothelioma
    Di Marzo, Domenico
    Forte, Iris Maria
    Indovina, Paola
    Di Gennaro, Elena
    Rizzo, Valeria
    Giorgi, Francesca
    Mattioli, Eliseo
    Iannuzzi, Carmelina Antonella
    Budillon, Alfredo
    Giordano, Antonio
    Pentimalli, Francesca
    CELL CYCLE, 2014, 13 (04) : 652 - 665
  • [45] p53 and MDM2 expression in malignant pleural mesothelioma; a series of 96 cases
    Galateau-Salle, F.
    Vergani, P.
    Morlais, F.
    Rouleau, V.
    Jaurand, M. C.
    Rolland, P.
    Paciencia, M.
    Pairon, J. C.
    Goldberg, M.
    Lounoy, G.
    LABORATORY INVESTIGATION, 2007, 87 : 321A - 321A
  • [46] P53 and MDM2 expression in malignant pleural mesothelioma; A series of 96 cases
    Galateau-Salle, F.
    Vergani, P.
    Morlais, F.
    Roudeau, V.
    Jaurand, M. C.
    Rolland, P.
    Paciencia, M.
    Pairon, J. C.
    Goldberg, M.
    Launoy, G.
    MODERN PATHOLOGY, 2007, 20 : 321A - 321A
  • [47] p53 in nonneoplastic CNS lesions: An immunohistochemical and gene sequencing study
    Kurtkaya-Yapicier, O
    Scheithauer, BW
    James, CD
    MODERN PATHOLOGY, 2002, 15 (01) : 300A - 300A
  • [48] P53 in nonneoplastic, CNS lesions: An immunohistochemical and gene sequencing study
    Kurtkaya-Yapicier, O
    Scheithauer, BW
    James, CD
    LABORATORY INVESTIGATION, 2002, 82 (01) : 300A - 300A
  • [49] Quantitative analysis of p53 protein in benign and malignant breast tissues
    Westhof, G
    Salmassi, A
    Mettler, L
    Jonat, W
    GEBURTSHILFE UND FRAUENHEILKUNDE, 1997, 57 (06) : 342 - 348
  • [50] EXPRESSION OF P53 PROTEIN IN BENIGN AND MALIGNANT EPIDERMAL PATHOLOGICAL CONDITIONS
    HELANDER, SD
    PETERS, MS
    PITTELKOW, MR
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 29 (05) : 741 - 748
12345